Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Selection on non-antigenic gene segments of seasonal influenza A virus and its impact on adaptive evolution.

Raghwani J, Thompson RN, Koelle K.

Virus Evol. 2017 Nov 9;3(2):vex034. doi: 10.1093/ve/vex034. eCollection 2017 Jul.

2.

Molecular Markers for Interspecies Transmission of Avian Influenza Viruses in Mammalian Hosts.

Lloren KKS, Lee T, Kwon JJ, Song MS.

Int J Mol Sci. 2017 Dec 13;18(12). pii: E2706. doi: 10.3390/ijms18122706. Review.

3.

Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.

Choi WS, Jeong JH, Kwon JJ, Ahn SJ, Lloren KKS, Kwon HI, Chae HB, Hwang J, Kim MH, Kim CJ, Webby RJ, Govorkova EA, Choi YK, Baek YH, Song MS.

J Virol. 2017 Dec 14;92(1). pii: e01580-17. doi: 10.1128/JVI.01580-17. Print 2018 Jan 1.

PMID:
29046464
4.

Adaptive mutations of neuraminidase stalk truncation and deglycosylation confer enhanced pathogenicity of influenza A viruses.

Park S, Il Kim J, Lee I, Bae JY, Yoo K, Nam M, Kim J, Sook Park M, Song KJ, Song JW, Kee SH, Park MS.

Sci Rep. 2017 Sep 7;7(1):10928. doi: 10.1038/s41598-017-11348-0.

5.

Mutation of the Putative Immunosuppressive Domain of the Retroviral Envelope Glycoprotein Compromises Infectivity.

Eksmond U, Jenkins B, Merkenschlager J, Mothes W, Stoye JP, Kassiotis G.

J Virol. 2017 Oct 13;91(21). pii: e01152-17. doi: 10.1128/JVI.01152-17. Print 2017 Nov 1.

6.

Characterization of influenza A(H1N1)pdm09 viruses isolated from Nepalese and Indian outbreak patients in early 2015.

Nakamura K, Shirakura M, Fujisaki S, Kishida N, Burke DF, Smith DJ, Kuwahara T, Takashita E, Takayama I, Nakauchi M, Chadha M, Potdar V, Bhushan A, Upadhyay BP, Shakya G, Odagiri T, Kageyama T, Watanabe S.

Influenza Other Respir Viruses. 2017 Sep;11(5):399-403. doi: 10.1111/irv.12469. Epub 2017 Aug 9.

7.

Generation and characterization of interferon-lambda 1-resistant H1N1 influenza A viruses.

Ilyushina NA, Lugovtsev VY, Samsonova AP, Sheikh FG, Bovin NV, Donnelly RP.

PLoS One. 2017 Jul 27;12(7):e0181999. doi: 10.1371/journal.pone.0181999. eCollection 2017.

8.

The role of nanotechnology in the treatment of viral infections.

Singh L, Kruger HG, Maguire GEM, Govender T, Parboosing R.

Ther Adv Infect Dis. 2017 Jul;4(4):105-131. doi: 10.1177/2049936117713593. Epub 2017 Jul 5. Review.

9.

Mitogenic stimulation accelerates influenza-induced mortality by increasing susceptibility of alveolar type II cells to infection.

Nikolaidis NM, Noel JG, Pitstick LB, Gardner JC, Uehara Y, Wu H, Saito A, Lewnard KE, Liu H, White MR, Hartshorn KL, McCormack FX.

Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):E6613-E6622. doi: 10.1073/pnas.1621172114. Epub 2017 Jul 24.

10.

Identification of Novel and Efficacious Chemical Compounds that Disturb Influenza A Virus Entry in vitro.

Khalil H, El Malah T, El Maksoud AIA, El Halfawy I, El Rashedy AA, El Hefnawy M.

Front Cell Infect Microbiol. 2017 Jun 30;7:304. doi: 10.3389/fcimb.2017.00304. eCollection 2017.

11.

New insights into influenza A specificity: an evolution of paradigms.

Ji Y, White YJ, Hadden JA, Grant OC, Woods RJ.

Curr Opin Struct Biol. 2017 Jun;44:219-231. doi: 10.1016/j.sbi.2017.06.001. Epub 2017 Jul 1. Review.

12.

Seasonal H3N2 and 2009 Pandemic H1N1 Influenza A Viruses Reassort Efficiently but Produce Attenuated Progeny.

Phipps KL, Marshall N, Tao H, Danzy S, Onuoha N, Steel J, Lowen AC.

J Virol. 2017 Aug 10;91(17). pii: e00830-17. doi: 10.1128/JVI.00830-17. Print 2017 Sep 1.

PMID:
28637755
13.

Progress of small molecular inhibitors in the development of anti-influenza virus agents.

Wu X, Wu X, Sun Q, Zhang C, Yang S, Li L, Jia Z.

Theranostics. 2017 Feb 8;7(4):826-845. doi: 10.7150/thno.17071. eCollection 2017. Review.

14.

pH Optimum of Hemagglutinin-Mediated Membrane Fusion Determines Sensitivity of Influenza A Viruses to the Interferon-Induced Antiviral State and IFITMs.

Gerlach T, Hensen L, Matrosovich T, Bergmann J, Winkler M, Peteranderl C, Klenk HD, Weber F, Herold S, Pöhlmann S, Matrosovich M.

J Virol. 2017 May 12;91(11). pii: e00246-17. doi: 10.1128/JVI.00246-17. Print 2017 Jun 1.

15.

Role of Neuraminidase in Influenza A(H7N9) Virus Receptor Binding.

Benton DJ, Wharton SA, Martin SR, McCauley JW.

J Virol. 2017 May 12;91(11). pii: e02293-16. doi: 10.1128/JVI.02293-16. Print 2017 Jun 1.

16.

Influenza A virus hemagglutinin and neuraminidase act as novel motile machinery.

Sakai T, Nishimura SI, Naito T, Saito M.

Sci Rep. 2017 Mar 27;7:45043. doi: 10.1038/srep45043.

17.

Heterologous Packaging Signals on Segment 4, but Not Segment 6 or Segment 8, Limit Influenza A Virus Reassortment.

White MC, Steel J, Lowen AC.

J Virol. 2017 May 12;91(11). pii: e00195-17. doi: 10.1128/JVI.00195-17. Print 2017 Jun 1.

18.

Distinct susceptibility and applicability of MDCK derivatives for influenza virus research.

Lin SC, Kappes MA, Chen MC, Lin CC, Wang TT.

PLoS One. 2017 Feb 16;12(2):e0172299. doi: 10.1371/journal.pone.0172299. eCollection 2017.

19.

Mutation of the Second Sialic Acid-Binding Site, Resulting in Reduced Neuraminidase Activity, Preceded the Emergence of H7N9 Influenza A Virus.

Dai M, McBride R, Dortmans JC, Peng W, Bakkers MJ, de Groot RJ, van Kuppeveld FJ, Paulson JC, de Vries E, de Haan CA.

J Virol. 2017 Apr 13;91(9). pii: e00049-17. doi: 10.1128/JVI.00049-17. Print 2017 May 1.

20.

Quantification of Influenza Neuraminidase Activity by Ultra-High Performance Liquid Chromatography and Isotope Dilution Mass Spectrometry.

Solano MI, Woolfitt AR, Williams TL, Pierce CL, Gubareva LV, Mishin V, Barr JR.

Anal Chem. 2017 Mar 7;89(5):3130-3137. doi: 10.1021/acs.analchem.6b04902. Epub 2017 Feb 21.

Supplemental Content

Support Center